SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sam Citron who wrote (14425)12/2/2004 11:08:35 AM
From: Biomaven  Read Replies (3) of 52153
 
ENZN is about at breakeven, and will likely move into profitability with royalties from Macugen. But Peg-intron is still the biggest driver and I don't really know where this is headed - the last years have been tough. Abelcet their anti-fungal is facing increased competition.

It's not real expensive in biotech terms, but it also looks like a tough couple of years ahead of them. Hard to see the stock going too far unless they decide to let themselves be munched.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News